Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma

Lorna McKinlay; Peter A. Williamson; Philip M. Short; Thomas Fardon; Brian J. Lipworth

doi:10.1111/j.1365-2125.2010.03795.x

Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma

Lorna McKinlay, Peter A. Williamson, Philip M. Short, Thomas Fardon, Brian J. Lipworth

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

AIM

The aim of the study was to evaluate the usefulness of inflammatory surrogates in determining step-down therapy in asthma.

METHODS

AMP challenge, serum eosinophil cationic protein (ECP), exhaled nitric oxide (eNO) and pulmonary function tests were recorded. Subjects were divided into two groups following high dose inhaled corticosteroids (ICS): Group A fixed dose ICS vs. Group B ICS alone and in combination with add on therapies.

RESULTS

No differences were seen in inflammatory measures between fixed dose ICS and reduced dose ICS alone or with combination therapies.

CONCLUSIONS

AMP challenge conferred no additional benefit in guiding step-down therapy. The role of inflammatory surrogates may still play a role in predicting failed step-down on an individual basis.

Original language	English
Pages (from-to)	128-131
Number of pages	4
Journal	British Journal of Clinical Pharmacology
Volume	71
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2125.2010.03795.x
Publication status	Published - Jan 2011

Keywords

Adenosine monophosphate
Asthma
Exhaled nitric oxide
Management
Serum cationic protein
Fluticasone propionate
Dose-response
Hyperresponsiveness
Formulations

Access to Document

10.1111/j.1365-2125.2010.03795.x

Cite this

@article{a2ec687dc5034b1c9dc2c1a010e937b7,

title = "Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma",

abstract = "AIMThe aim of the study was to evaluate the usefulness of inflammatory surrogates in determining step-down therapy in asthma.METHODSAMP challenge, serum eosinophil cationic protein (ECP), exhaled nitric oxide (eNO) and pulmonary function tests were recorded. Subjects were divided into two groups following high dose inhaled corticosteroids (ICS): Group A fixed dose ICS vs. Group B ICS alone and in combination with add on therapies.RESULTSNo differences were seen in inflammatory measures between fixed dose ICS and reduced dose ICS alone or with combination therapies.CONCLUSIONSAMP challenge conferred no additional benefit in guiding step-down therapy. The role of inflammatory surrogates may still play a role in predicting failed step-down on an individual basis.",

keywords = "Adenosine monophosphate, Asthma, Exhaled nitric oxide, Management, Serum cationic protein, Fluticasone propionate, Dose-response, Hyperresponsiveness, Formulations",

author = "Lorna McKinlay and Williamson, {Peter A.} and Short, {Philip M.} and Thomas Fardon and Lipworth, {Brian J.}",

year = "2011",

month = jan,

doi = "10.1111/j.1365-2125.2010.03795.x",

language = "English",

volume = "71",

pages = "128--131",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma

AU - McKinlay, Lorna

AU - Williamson, Peter A.

AU - Short, Philip M.

AU - Fardon, Thomas

AU - Lipworth, Brian J.

PY - 2011/1

Y1 - 2011/1

N2 - AIMThe aim of the study was to evaluate the usefulness of inflammatory surrogates in determining step-down therapy in asthma.METHODSAMP challenge, serum eosinophil cationic protein (ECP), exhaled nitric oxide (eNO) and pulmonary function tests were recorded. Subjects were divided into two groups following high dose inhaled corticosteroids (ICS): Group A fixed dose ICS vs. Group B ICS alone and in combination with add on therapies.RESULTSNo differences were seen in inflammatory measures between fixed dose ICS and reduced dose ICS alone or with combination therapies.CONCLUSIONSAMP challenge conferred no additional benefit in guiding step-down therapy. The role of inflammatory surrogates may still play a role in predicting failed step-down on an individual basis.

AB - AIMThe aim of the study was to evaluate the usefulness of inflammatory surrogates in determining step-down therapy in asthma.METHODSAMP challenge, serum eosinophil cationic protein (ECP), exhaled nitric oxide (eNO) and pulmonary function tests were recorded. Subjects were divided into two groups following high dose inhaled corticosteroids (ICS): Group A fixed dose ICS vs. Group B ICS alone and in combination with add on therapies.RESULTSNo differences were seen in inflammatory measures between fixed dose ICS and reduced dose ICS alone or with combination therapies.CONCLUSIONSAMP challenge conferred no additional benefit in guiding step-down therapy. The role of inflammatory surrogates may still play a role in predicting failed step-down on an individual basis.

KW - Adenosine monophosphate

KW - Asthma

KW - Exhaled nitric oxide

KW - Management

KW - Serum cationic protein

KW - Fluticasone propionate

KW - Dose-response

KW - Hyperresponsiveness

KW - Formulations

U2 - 10.1111/j.1365-2125.2010.03795.x

DO - 10.1111/j.1365-2125.2010.03795.x

M3 - Article

C2 - 21143509

SN - 0306-5251

VL - 71

SP - 128

EP - 131

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -

Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma

Abstract

Keywords

Access to Document

Fingerprint

Cite this